New York Times: Obesity Treatment Relieves Heart Failure Symptoms, Drugmaker’s Study Finds

One of the leading new obesity drugs, Wegovy, eased symptoms and raised the quality of life of patients with obesity and a common type of heart failure, a study funded by the drug’s maker found, adding to the evidence that the medications can produce health benefits beyond weight loss.

The study, published on Friday in The New England Journal of Medicine, evaluated the drug in people with a condition known as preserved ejection fraction in which the heart pumps normally but has lost the flexibility needed to fill with blood. The condition accounts for roughly half of all heart failure cases.

Dr. Mikhail Kosiborod, cardiologist and vice president for research at Saint Luke’s Mid America Heart Institute, was the lead author of the study and presented the results in Amsterdam at the annual meeting of the European Society of Cardiology (ESC).

Read the full article, New York Times: Obesity Treatment Relieves Heart Failure Symptoms, Drugmaker’s Study Finds

Related Content

Aug. 25, 2023

CNN: Weight-Loss Drug Wegovy Produces ‘Largest Benefit Ever Seen’ for Patients with Most Common Form of Heart Failure, Trial Finds

The diabetes and weight loss drug semaglutide significantly reduced symptoms and improved quality of life in people with obesity and the most common form of heart failure in a clinical trial.
Aug. 26, 2023

Good Morning America: New Study Highlights Benefits to Weight Loss Drugs

Semaglutide, the active ingredient on weight loss drugs Wegovy and Ozempic, shows evidence that the drug may also help reduce the risks of heart disease.
Aug. 25, 2023

U.S. News & World Report: Wegovy May Be Valuable New Option for Heart Failure Patients

Weight-loss drug Wegovy (semaglutide) and its diabetes-focused cousin, Ozempic, have already upended the treatment of both obesity and diabetes, with sales of both drugs skyrocketing.